FDA approves Viatris's Ryzumvi eye drops for presbyopia in adults
The phentolamine 0.75% drop was already approved to reverse pupil dilation; Viatris is seeking a US partner to sell it for presbyopia.

The Hugging Face release lists 27B active parameters, 1M-token context and text, image and video input, aimed at long-horizon agent work.
The phentolamine 0.75% drop was already approved to reverse pupil dilation; Viatris is seeking a US partner to sell it for presbyopia.
The change to the Foreign Trade Act is tied to the U.S.-Taiwan trade agreement; no bill text or implementation date has been published.
Diluted EPS was NT$29.43; the company's management report credits high-performance computing demand.
A public meeting is set for October 28 and comments are open through December 11; changes to guidance and rules may follow.
Approval rests on bioequivalence and a 31-patient study with full dose delivery in 99.8% of injections; launch is expected in Q1 2027.

Six METR staff get access comparable to internal risk teams; Anthropic may require only narrow redactions, which METR can publicly challenge.

It has 80 billion active parameters and trained on 16,000 GB200 GPUs for 38 days; post-training continues and no release date is set.
FT, CNBC and Axios report adjusted profitability and positive cash flow ahead of a possible IPO; Anthropic has not published the figures.

The Nature Machine Intelligence paper reports 1,110 sensing units per cm² read at 100 frames a second; reviewers flagged power use and robustness.
The centre sits in the Ray Dolby Centre; the announcement is a partnership opening rather than a new hardware result.
TMB-high is now defined as at least 13 mutations per megabase, down from 10, after benefit was not confirmed between 10 and 13; response rate was 36%.